BEXLUTRY Enters GEP-NET Market as Supply Play, Not Clinical Differentiator — Execution Risk Dominates

FDA Approves Curium's BEXLUTRY for SSTR-Positive GEP-NETs

Curium™ announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for BEXLUTRY™ (lutetium Lu 177 dotatate injection) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. BEXLUTRY™ is a radioligand therapy, approved via the FDA’s 505(b)(2) pathway as an equivalent to LUTATHERA®. This approval marks Curium's expansion into oncology therapeutics, leveraging its nuclear medicine expertise to provide a full diagnosis-to-therapy capability for the NET community. The company emphasizes its vertical integration to ensure a reliable supply and scalable delivery of this new therapy.

• BEXLUTRY™ received FDA approval through the 505(b)(2) pathway, signifying its recognition as a radioligand equivalent to LUTATHERA® (lutetium Lu 177 dotatate). This approval was supported by published evidence and targeted bridging data demonstrating a similar biological and chemical profile, allowing for a streamlined regulatory process for this SSTR-targeted therapy.
• This approval represents a significant strategic expansion for Curium™ into oncology therapeutics, building on over a century of experience in nuclear medicine. The company aims to provide a comprehensive diagnosis-to-therapy solution for the neuroendocrine tumor (NET) community, reinforcing its commitment to advancing patient care in this area.
• Curium™ highlights its unique position as the only vertically integrated, lutetium-based NETs therapy manufacturer. This integration is crucial for supporting a reliable supply of BEXLUTRY™ and enabling sites of care to scale radioligand therapy delivery, ensuring consistent access and predictable scheduling for eligible patients.

The Persistent Challenges in Treating SSTR-Positive GEP-NETs

Despite meaningful advances in systemic therapy, the management of somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) remains constrained by a constellation of biological, clinical, and therapeutic challenges. These limitations span the full anatomical spectrum — foregut, midgut, and hindgut — and reflect the profound heterogeneity of this tumor class.

• Resistance to somatostatin analogs (SSAs): The first-generation SSAs octreotide and lanreotide constitute the cornerstone of treatment for functioning, progressive functioning, and non-functioning GEP-NETs; however, their therapeutic response is frequently attenuated or diminished by the development of resistance. The phenomenon of resistance is complex, implicating additional epigenetic and genetic mechanisms, and the exact mechanisms are not fully understood. Symptomatic control of carcinoid syndrome is reduced by approximately 50% within the first year of SSA therapy.

• Site-dependent variability in SSTR2 expression: SSTR2 expression profiles in GEP-NETs differ by primary site, and the difference between foregut and hindgut NETs may be derived from the SSTR2 status of normal neuroendocrine cell counterparts. In the normal mucosa, neuroendocrine cells in the rectum have significantly lower positive rates of SSTR2 than those in the stomach and duodenum. SSTR2 immunoreactivity is significantly negatively correlated with the Ki-67 labeling index in foregut NETs and positively correlated in hindgut NETs, complicating uniform predictive strategies across anatomical subtypes.

• Persistent hematologic dysfunction (PHD) following PRRT: Peptide receptor radionuclide therapy (PRRT) with ^177Lu-DOTATATE may induce long-term toxicity to the bone marrow. In a cohort of 274 GEP-NET patients, 4% developed PHD, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), MDS/MPN, or bone marrow aplasia. The median latency period at diagnosis was 41 months (range, 15–84 months), and the relative risk for developing a hematopoietic neoplasm was 2.7 (95% confidence interval, 0.7–10.0). No risk factors for PHD could be identified, not even bone metastasis or estimated bone marrow dose.

• Diagnostic and therapeutic complexity in G3 GEP-NETs: The 2019 WHO classification subdivided Ki-67 >20% GEP-NETs into well-differentiated grade 3 (G3) NETs and poorly differentiated neuroendocrine carcinomas (NECs), yet the scientific evidence supporting treatment of G3 GEP-NETs is limited, with most studies retrospective and a median of only 15 patients per study. For advanced disease, capecitabine and temozolomide represents the most effective option identified, with a response rate, median progression-free survival, and median overall survival up to 37.9%, 20.6 months, and 41.2 months, respectively — but the level of evidence for treatment recommendations remains low.

• Systemic inflammation as a prognostic barrier in PRRT: Pre-treatment blood-based inflammatory biomarkers — including C-reactive protein (CRP), absolute neutrophil count (ANC), and the Platelet × CRP multiplier (PCM) — were significantly higher in non-responders to PRRT. A CRP cut-off of 2.5 mg/L revealed a significant outcome difference, with median progression-free survival of 508 days versus not yet reached (HR = 4.52; 95% CI, 1.27 to 16.18; p = 0.02) in patients with high versus low CRP. Tumor-driven systemic inflammatory networks may be associated with treatment response, change in tumor burden, and prognosis in patients with GEP-NETs receiving PRRT.

• Suboptimal real-world adherence to treatment standards: In a real-world U.S. claims analysis, dose escalations and dosing deviations outside of label were noted for SSAs, with approximately 12.7% of octreotide patients receiving doses above label (>30 mg every 4 weeks). Variances between chart review and claims data were significant, underscoring gaps between clinical trial evidence and community practice in GEP-NET management.

How Radioligand Therapy is Evolving the GEP-NETs Landscape

The treatment landscape for somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has been substantially reshaped over the past several years, with peptide receptor radionuclide therapy (PRRT) emerging as a pivotal advance. Lu-177-DOTATATE, the first commercially available PRRT product, was approved following the NETTER-1 trial in G1 and G2 gastroenteric NETs, demonstrating a median progression-free survival (PFS) of 28.4 months compared to 8.5 months for octreotide LAR 60 mg monthly. This established PRRT as an "established second- or third-line treatment option" for patients with SSTR-positive advanced well-differentiated GEP-NETs, with clinical evidence confirming tumor control, lower risks of disease progression or death, and improved quality of life. A second pivotal study, COMPETE, is currently in progress, comparing no carrier-added Lu-177-DOTATOC to the mTOR inhibitor everolimus in both gastroenteric NETs and pancreatic NETs (PNETs). Two additional studies, NETTER-2 and COMPOSE, are underway in patients with high-grade G2 and G3 NETs, extending the investigational scope of PRRT beyond the G1/G2 population where efficacy is already well-characterized.

Beyond PRRT, somatostatin analogs (SSAs) remain foundational in the management of advanced GEP-NETs, with both octreotide long-acting release (LAR) and lanreotide Autogel (somatuline depot) approved as first-line options. A retrospective study at Emory University (n = 105) found no statistically significant difference in overall median PFS between octreotide LAR (12 months; 95% CI, 6–18 months) and somatuline depot (10.8 months; 95% CI, 6–15.6 months), though a statistically significant difference was observed in the G2 subgroup (12 vs. 7.2 months, respectively; p = 0.0372). For patients progressing on standard 4-weekly SSA regimens, above-label dosing at 3-weekly intervals has demonstrated a disease control rate of 50% and a median PFS of 25.0 months (95% CI 16.9–33.1), with patients exhibiting small bowel/colorectal primaries, a Ki-67 index <5%, and absence of or limited extrahepatic metastases identified as more likely to benefit. Real-world Canadian data further showed that switching between long-acting SSAs reduced breakthrough medication claims by 59.1% overall, with a more pronounced reduction of 66.5% observed when switching from octreotide LAR to lanreotide Autogel.

Multikinase inhibitors (MKIs) and novel targeted agents have also contributed to the evolving treatment paradigm. Sunitinib and everolimus remain approved systemic options, with everolimus demonstrating improved PFS in advanced GEP-NETs. Emerging agents including surufatinib — a novel oral tyrosine kinase inhibitor targeting VEGFR 1, 2, and 3, FGFR1, and CSF1R — have shown encouraging antitumor activity. In a Phase 1/1b US study (NCT02549937), the recommended Phase 2 dose was established at 300 mg once daily, with median PFS of 15.2 months (95% CI: 5.2, not evaluable) for pNET and 11.5 months (95% CI: 6.5, 11.5) for epNET expansion cohorts, and the most frequent treatment-emergent adverse events being fatigue (46.9%), hypertension (43.8%), proteinuria (37.5%), and diarrhea (34.4%). Evidence from the CABINET trial and data on agents such as axitinib, pazopanib, and lenvatinib are also contributing to the MKI evidence base, though optimal treatment sequencing and predictive biomarkers remain unresolved challenges across the GEP-NET treatment landscape.

Key Safety and Tolerability Insights for Lutetium Lu 177 Dotatate

Published literature characterizes the safety and tolerability profile of lutetium Lu 177 dotatate (Lutathera) across multiple organ systems and timeframes, spanning acute infusion-related events through long-term hematologic sequelae. Data from the pivotal NETTER-1 phase III trial, real-world pharmacovigilance analyses, and institutional case series collectively define a multidimensional risk landscape that clinical teams must monitor across the treatment continuum.

• Hematologic toxicity in NETTER-1: In the phase III NETTER-1 trial, grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia occurred in 1%, 2%, and 9%, respectively, of patients in the Lu-Dotatate group, with no evidence of renal toxic effects during the observed time frame. Clinically significant myelosuppression was therefore present in fewer than 10% of patients.

• Therapy-related myeloid neoplasms (tMN): Long-term hematologic toxicities, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), are increasingly recognized as rare but severe complications of peptide receptor radionuclide therapy (PRRT). In a cohort of 274 gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients treated with 177Lu-DOTATATE, 4% developed persistent hematologic dysfunction (PHD): 8 patients (2.9%) developed a hematopoietic neoplasm (4 MDS, 1 AML, 1 MPN, and 2 MDS/MPN) and 3 patients (1.1%) developed bone marrow failure characterized by cytopenia and bone marrow aplasia. The median latency period at diagnosis was 41 months (range, 15–84 months), and the relative risk for developing a hematopoietic neoplasm was 2.7 (95% confidence interval, 0.7–10.0). No risk factors for PHD could be identified in this GEP-NET population.

• Carcinoid crisis: Carcinoid crisis is a rare but potentially life-threatening complication, with an estimated incidence of 1–2% of treatment recipients. It is most often encountered within 12–48 hours of receiving the first treatment dose, with the most common symptoms being nausea/vomiting, flushing, and diarrhea. Patients with midgut tumor location, higher tumor burden, and the presence of metastasis carry increased risk.

• Gastrointestinal and infusion-related toxicities: A FAERS-based pharmacovigilance analysis identified higher risks of gastrointestinal toxicities for Lutathera, including intestinal obstruction (ROR 5.33, 95% CI: 3.82–7.43) and infection-related events such as liver abscess (ROR 26.16, 95% CI: 15.73–43.51). Shared adverse reactions with Pluvicto include pleural effusion (ROR 1.68, 95% CI: 1.03–2.74) and pulmonary embolism (ROR 1.06, 95% CI: 0.61–1.82). Separately, nausea and vomiting associated with the co-infused amino acid solution were substantially reduced when compounded l-arginine 2.5%/l-lysine 2.5% in 0.9% NaCl was used in place of commercial parenteral nutrition formulas: 17% of patients in the arginine/lysine cohort experienced nausea versus 100% in the early-access program group receiving 15% Clinisol (P < 0.0001).

• Renal toxicity: With the conventional 4-hour renoprotective amino acid infusion protocol, there was no significant change in glomerular filtration rate (GFR) (1.2 ml/min mean increase from baseline; 95% CI −6.9 to 4.4 ml/min) and no grade 3 or 4 nephrotoxicity at the end of induction peptide receptor chemoradionuclide therapy (PRCRT). The long-term decline in GFR after a median follow-up of 22 months was 2.2 ml/min per year. In patients with stage 4 chronic kidney disease (eGFR 15–29 mL/min/1.73m²), treatment has been reported on a case-by-case basis with hemodialysis support, with dialysis performed at 24 hours after administration as recommended by practice guidelines.

• Quality of life: In the NETTER-1 phase III study, time to deterioration (TTD) in health-related quality of life was significantly longer in the Lu-Dotatate arm versus the control arm across multiple domains, including global health status (hazard ratio [HR], 0.406), physical functioning (HR, 0.518), fatigue (HR, 0.621), pain (HR, 0.566), and diarrhea (HR, 0.473). Differences in median TTD were clinically significant in several domains: 28.8 months versus 6.1 months for global health status, and 25.2 months versus 11.5 months for physical functioning.

Curium's BEXLUTRY™: A New Force in GEP-NET Radioligand Therapy

The recent FDA approval of BEXLUTRY™ marks a pivotal moment in the management of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), introducing a new player into a therapeutic space previously dominated by a single approved radioligand therapy. This development underscores the growing importance of the theranostic paradigm, where diagnostic imaging with somatostatin receptor (SSTR) PET/CT guides patient selection for targeted radionuclide therapy. Existing evidence consistently demonstrates that peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE offers significant benefits in progression-free survival, overall survival, and quality of life for patients with well-differentiated GEP-NETs.

Curium's entry into this market, particularly through the 505(b)(2) pathway, signals a strategic intent to compete directly by offering an equivalent therapeutic option. A key differentiator highlighted by the company is its vertical integration, a crucial factor in the radiopharmaceutical sector where complex logistics and supply chain reliability are paramount. This approach could enhance treatment accessibility and ensure a more consistent supply, addressing a common challenge in specialized nuclear medicine.

However, as with any potent therapy, important considerations remain. Clinicians must be aware of the potential for adverse events, including the rare but serious risk of carcinoid crisis, which requires prompt recognition and management, especially in high-risk patients. Furthermore, hematotoxicity, such as lymphocytopenia and thrombocytopenia, is a known side effect of PRRT, necessitating careful monitoring of blood counts throughout treatment. The potential for kidney toxicity due to the renal excretion of the radiolabeled agent also underscores the importance of kidney protection strategies and long-term renal function surveillance. This new approval will likely foster innovation, potentially leading to improved patient outcomes through enhanced access and continued optimization of treatment protocols.